Hiddo J Lambers Heerspink Selected Research

Proteinuria

9/2015	Assessing the Validity of Surrogate Outcomes for ESRD: A Meta-Analysis.
2/2015	Fibroblast growth factor 23 and the antiproteinuric response to dietary sodium restriction during renin-angiotensin-aldosterone system blockade.
2/2013	Improving the efficacy of RAAS blockade in patients with chronic kidney disease.
7/2011	Moderate dietary sodium restriction added to angiotensin converting enzyme inhibition compared with dual blockade in lowering proteinuria and blood pressure: randomised controlled trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Hiddo J Lambers Heerspink Research Topics

Disease

24	Type 2 Diabetes Mellitus (MODY) 01/2023 - 08/2010
23	Albuminuria 01/2023 - 10/2008
18	Chronic Kidney Failure (Chronic Renal Failure) 01/2023 - 08/2010
17	Diabetic Nephropathies (Diabetic Nephropathy) 01/2023 - 07/2011
12	Chronic Renal Insufficiency 01/2023 - 09/2010
9	Heart Failure 09/2016 - 12/2009
7	Cardiovascular Diseases (Cardiovascular Disease) 01/2016 - 11/2006
5	Body Weight (Weight, Body) 01/2021 - 12/2013
5	Hypertension (High Blood Pressure) 03/2014 - 09/2010
4	Kidney Diseases (Kidney Disease) 09/2015 - 09/2012
4	Proteinuria 09/2015 - 07/2011
3	Disease Progression 01/2016 - 01/2015
3	Fibrosis (Cirrhosis) 01/2015 - 01/2013
3	Inflammation (Inflammations) 01/2015 - 01/2013
3	Renal Insufficiency (Renal Failure) 12/2014 - 01/2012
2	Insulin Resistance 01/2023 - 11/2019
2	Stroke (Strokes) 09/2015 - 11/2014
2	Myocardial Infarction 09/2015 - 11/2014
1	Non-alcoholic Fatty Liver Disease 11/2019
1	Arteritis 11/2019
1	Peripheral Arterial Disease 01/2016
1	Weight Gain 09/2015
1	Edema (Dropsy) 05/2014
1	Coronary Disease (Coronary Heart Disease) 03/2014
1	Anemia 11/2013
1	Nephrosis 01/2013
1	Diabetes Mellitus 01/2012

Drug/Important Bio-Agent (IBA)

23	CreatinineIBA 01/2023 - 10/2008
11	AlbuminsIBA 01/2023 - 10/2008
11	Biomarkers (Surrogate Marker)IBA 01/2021 - 11/2006
10	Angiotensin IIIBA 09/2015 - 08/2010
10	Losartan (Cozaar)FDA LinkGeneric 09/2015 - 08/2010
8	Irbesartan FDA LinkGeneric 09/2015 - 09/2011
7	Angiotensin Receptor AntagonistsIBA 01/2016 - 06/2011
6	Dietary SodiumIBA 04/2017 - 07/2011
6	Hemoglobins (Hemoglobin)IBA 05/2016 - 06/2013
5	SodiumIBA 04/2017 - 07/2011
4	AtrasentanIBA 01/2023 - 05/2014
4	Insulin (Novolin)FDA Link 09/2015 - 01/2012
4	Brain Natriuretic Peptide (Natrecor)FDA Link 08/2013 - 12/2009
3	Endothelin Receptor AntagonistsIBA 01/2023 - 03/2014
3	Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)IBA 04/2017 - 07/2011
3	bardoxolone methylIBA 12/2013 - 01/2013
2	Glycated Hemoglobin (Glycosylated Hemoglobin)IBA 01/2021 - 09/2015
2	Glucose (Dextrose)FDA LinkGeneric 11/2019 - 07/2013
2	Calcitriol Receptors (Calcitriol Receptor)IBA 04/2017 - 01/2016
2	AngiotensinsIBA 04/2017 - 09/2012
2	ReninIBA 04/2017 - 08/2013
2	AldosteroneIBA 04/2017 - 09/2012
2	paricalcitol (Zemplar)FDA Link 04/2017 - 01/2016
2	Endothelin A ReceptorIBA 05/2016 - 05/2014
2	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 01/2016 - 12/2012
2	Proteins (Proteins, Gene)FDA Link 02/2015 - 08/2010
2	pro-brain natriuretic peptide (1-76)IBA 03/2014 - 02/2011
2	Troponin T (Troponin T1)IBA 04/2013 - 09/2012
2	SaltsIBA 09/2012 - 07/2011
2	Angiotensin Receptors (Angiotensin II Receptor)IBA 09/2011 - 07/2011
1	LDL CholesterolIBA 01/2021
1	CanagliflozinIBA 01/2021
1	C-Reactive ProteinIBA 11/2019
1	LeptinIBA 11/2019
1	AdiponectinIBA 11/2019
1	5'-palmitoyl cytarabine (PLAC)IBA 04/2017
1	Ramipril (Altace)FDA LinkGeneric 04/2017
1	Dihydrotachysterol (AT 10)IBA 04/2017
1	Calcitriol (Calcijex)FDA LinkGeneric 09/2016
1	Parathyroid Hormone (Parathormone)IBA 09/2016
1	Calcifediol (Calcidiol)FDA Link 09/2016
1	CholesterolIBA 05/2016
1	Sulfates (Sulfates, Inorganic)IBA 01/2016
1	Syntex adjuvant formulationIBA 01/2016
1	A 19IBA 01/2016
1	GlycosaminoglycansIBA 12/2015
1	Endothelin A Receptor AntagonistsIBA 09/2015
1	Bicarbonates (Hydrogen Carbonate)IBA 09/2015
1	Alanine Transaminase (SGPT)IBA 08/2014
1	AntioxidantsIBA 08/2014
1	BilirubinIBA 08/2014
1	Aspartate Aminotransferases (Aspartate Transaminase)IBA 08/2014
1	LipidsIBA 05/2014
1	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 03/2014
1	AvosentanIBA 03/2014
1	Vitamin D FDA LinkGeneric 08/2013
1	Cholecalciferol (Vitamin D3)FDA Link 08/2013
1	Natriuretic PeptidesIBA 08/2013
1	Trinitrotoluene (TNT)IBA 04/2013
1	CollagenIBA 01/2013
1	Vitamin D-Binding ProteinIBA 01/2013
1	TriterpenesIBA 01/2013
1	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2013
1	Cystatin CIBA 01/2013
1	Mineralocorticoid Receptor AntagonistsIBA 12/2012
1	PotassiumIBA 12/2012
1	Chymosin (Rennin)IBA 09/2012
1	Antihypertensive Agents (Antihypertensives)IBA 08/2012

Therapy/Procedure

10	Therapeutics 12/2015 - 09/2010
2	Sodium-Restricted Diet (Diet, Sodium Restricted) 02/2015 - 07/2011
1	Precision Medicine 08/2015
1	Aftercare (After-Treatment) 03/2014
1	Renal Replacement Therapy (Therapies, Renal Replacement) 01/2012